Chapter 1510

"This is sildenafil."

"I can't see anything."

"You say this medicine is really interesting. A little thing can sell for hundreds of millions of dollars."

A group of laymen around sildenafil API, issued bursts of emotion.

Sildenafil, which is used for clinical trials, does not need to be dyed. It uses pure white starch and some raw materials to form small tablets. It has neither taste nor appearance.

If medical experts discuss with each other, we can say something new about acetylcholine.

However, in the eyes of a group of bankers who deal with money all day long, it's not true.

"Here comes Professor Yang." Someone saw Yang Rui and immediately called out.

Several bank cadres of China Rural Construction Engineering immediately straightened up and showed cordial smiles.

"Here comes Professor Yang."

"Congratulations on the patent medicine."

"I wish you success in your experiment."

Several cadres are like paying a new year's call, bowing their hands and saying auspicious things.

What you said is true.

Pfizer finally sold sildenafil to Yang Rui, but it offered a high price, to add $180 million! What's more, it's still a milestone - if you make a finished antihypertensive drug, whether it's listed in any country in the world, you need to add US $200 million, and then, if it's listed in Europe or the United States, you need to add US $200 million.

That is to say, if sildenafil is sold in the United States, Pfizer will take us $580 million no matter how much it is sold.

It's not over yet. If the sales are good, that is, if the annual sales exceed 100 million US dollars, Pfizer will take 18% -- 18% of the sales, which will be converted into the profit. How can it have 20% or 30%, and it's still a milestone... If the sales exceed 1 billion US dollars and become a blockbuster, Pfizer will take 25% of the sales revenue.

It's insane.

To be honest, such an offer means that Pfizer can make it.

That is, Yang Rui can give it out.

Pharmaceutical companies such as Jericho do not necessarily have such courage.

The highest status of the milestone is US $580 million, plus 25% of the sales volume. The realization of the latter is that the sales volume exceeds US $1 billion, which is equivalent to US $250 million a year. The patent period of 15 consecutive years is US $3.8 billion.

A patented compound that has just passed the first phase of clinical trials has sold $180 million offline and $3.8 billion online. It is also one of the highest prices in the pharmaceutical industry that hasn't come in 90 years.

This is the result of Yang Rui's argument - of course, in order to focus the milestone on one point of anti pressure drugs, Yang Rui also put a little water.

Still, as a compound, the price is high enough.

Even if it's a finished drug, it's OK to sell hundreds of millions of dollars.

Double digit trading is not very common.

Even foreign enterprises such as Jielikang rarely give such a big milestone deal. For example, Yang Rui's deferonone is only the starting price of sildenafil from the milestone to the end. He still sells seven active compounds together.

This is the case for large pharmaceutical companies. On the one hand, they squeeze small biotechnology companies; on the other hand, they fill the market space with strong capital.

If it is not for the background of the Chinese market, Yang Rui will not be able to pull out a high price.

Of course, the current high price is not a problem for Yang Rui.

All the milestones are for the antihypertensive effect of sildenafil, not for other indications. Although Pfizer is not willing to sign such a contract, it is also recognized by holding its nose.

In fact, most of the drugs have additional effects. In professional terms, they can be used for other indications.

In short, the side effects of drugs can be used as new indications of drugs.

For example, the most common form of diarrhea.

Diarrhea is a side effect of many drugs, but if the effect of diarrhea is good, the drugs that are easy to produce diarrhea can naturally be used as laxatives.

On the other hand, some drugs can cause constipation, so if the effect of constipation is good, can it be made into antidiarrheal?

Another example is tachycardia, a common side effect of antihypertensive drugs. For many patients, especially the elderly patients, this is not good, but for patients with bradycardia, this is not a bad thing, so, dada, a drug that can treat bradycardia, has come out fresh, and its side effect is to reduce blood pressureIn the same way, the side effect of some drugs is to lower the heart rate, so for patients with tachycardia, it can play a role again.

Thus, it can be seen that in the era of chemical medicine, the emergence of universal medicine is impossible.

Your medicine can't both cause diarrhea and stop diarrhea, can't both reduce blood pressure and raise blood pressure, can't both raise heart rate and lower heart rate.

Aspirin has been called a miracle drug. It can reduce inflammation, relieve pain, cure cold, inhibit platelet and prevent stroke. Even so, try to give aspirin to the nobles with hemophilia. They are willing to break eight scepters and let you pay for the gems.

For pharmaceutical companies, developing new indications for a drug is a matter of increasing profits.

Because animal experiments and clinical phase I and phase II are not needed, as long as the clinical phase III proves its curative effect, the cost is relatively low.

However, not every drug is a miracle drug of aspirin. In fact, few drugs with new indications can perform well, so it is not easy to increase their sales.

On the other hand, the patent period is not endless. The general patent period of a drug is slightly more than 15 years, and the extra part is usually the additional patent period applied, but it is also single digit. In other words, there are very few patent drugs that can monopolize sales for 25 years.

For the development of new indications, the "slightly more" part is added, which is equivalent to the increase of single digit patent period with the follow-up cost of clinical phase III and phase IV. It's not sure whether it's cost-effective or not.

Most of the time, the development of new indications is not so much the discovery of new uses of drugs as the trick of pharmaceutical companies to extend the patent period.

If you think about it further, the new indications of drugs are equivalent to side effects. The better the curative effect of new indications is, the stronger and clearer the side effects will be. For a drug, it is a double-edged sword. Pharmaceutical companies would rather have a drug with minimal side effects and no new indications than a drug with extremely strong side effects, There are many drugs with new indications.

For example, the original indication of a drug is equivalent to the box office of a cinema. It is the main way for a company to make money. And the new indications are equivalent to the sales revenue of DVD, Blu ray disc, peripheral and so on. Some companies are good at these and make money through this, but they are not mainstream and unstable after all.

At Yang Rui's insistence, Pfizer gave up part of its later profits and focused on its main revenue. It also has its own routine.

In terms of profit and loss alone, they have made a profit since Yang Rui's 180 million US dollars came to the account, and the rest is net profit.

Of course, it is impossible for Yang Rui to give us $180 million at a time.

Through the coordination of several big men, Yang Rui borrowed the money from the four major branches of the construction industry and agriculture in the name of Huarui company. Each family took on tens of millions of different quotas, and each one was pale with horror.

What's more, Yang Rui has no money to pay for the milestone of US $200 million plus US $200 million in the later stage. No matter how much the sales are, it is rare for him to make drugs with annual sales of US $200 million and US $300 million in the early stage.

Pfizer naturally can't let its well-designed milestone drift away. Let alone Yang Rui, who doesn't have so much money, can't even have it. The development cycle of a drug is often ten years. During this period, what should he do if he has spent all his money?

Therefore, the workers and peasants in the construction also give Yang Rui guarantee.

5.8 In the view of banks, they take more risks than Yang Rui.

It can be seen from the importance they attached to the clinical trial center of Hedong university that the four major departments sent special personnel from the headquarters to take charge of this matter. After the animal experiment and the repeated experiment of phase I clinical trial were completed, the cadres at the deputy general level came to inspect.

I can't help it. Although the country has gradually gained some money in the past two years and can hardly afford to spend tens of millions of dollars, the expenditure of hundreds of millions of dollars is still very serious. What can be compared with this is the construction of some infrastructure projects, such as railway, highway, bridge, telecommunication, power grid, hydropower station, etc.

Compared with those projects that can be seen and felt and can be charged after construction, the R & D of sildenafil is really not a worry.

Yang Rui is not ready to let them worry about it. He is not ready to let them worry about it

"No one dares to say 100% about scientific research. We will do our best, and we should keep an open mind. "

"Although our clinical trial center has just been built and lacks experience, as long as we grasp the opportunity, we will soon become a mature team."

"The animal experiment and phase I clinical trial of sildenafil, that is, the safety experiment is very good. Phase II is a completely unfamiliar blank field, and foreigners have not done it. We are making history every step. Please accompany me to witness it."Several senior bank cadres are going crazy.

In the past, when I went to inspect the loan enterprises, even if they had a meal, they would pat their chest and spit out some fresh abalone to prove it.

Is that the attitude you have in scientific research?

Can you have some confidence?

It used to be loan companies that let us come here with confidence.

Witness history?

Who wants to witness history?

Hundreds of millions of dollars!

How many trips to Paris!

Paris

Milan

Big legs

Roast elbow

Bikini

Blonde hair and blue eyes

A group of bank cadres covered their chests and looked at the large ward behind the single-sided glass. They only felt that their blood pressure was out of control.